Obstetrics

The Department of Obstetrics of the Guangzhou Medical University Affiliated Women and Children’s Medical Center is a strong department integrating clinical care, teaching, and research. It is a national specialty for characteristic maternal and perinatal healthcare, a national demonstration unit for specialized maternal and perinatal healthcare, a national demonstration base for quality services for maternal and infant safety, a high-level specialty in Guangdong Province, the Guangdong Provincial Center for the Treatment of Critically Ill Pregnant and Postpartum Women, a Guangdong Provincial Key Clinical Specialty, a Guangdong Provincial Obstetric Quality Monitoring Sentinel Unit, the strongest department among hospitals in Guangdong, a Guangdong Provincial Key Medical Specialty, the Guangzhou Key Laboratory of Maternal-Fetal Medicine Research, a Guangzhou specialty for maternal and perinatal healthcare, a Guangzhou Key Clinical Specialty, and the top-level network specialty for maternal and child medical care in Guangzhou. The Department of Obstetrics has successively received numerous national, provincial, and municipal specialty designations and honors. In 2020, it received the title of “National Demonstration Unit for Quality Services for Maternal and Infant Safety” and won the First Prize of the National Maternal and Child Health Science and Technology Award; in 2021, it was selected as one of the strongest departments in Guangdong hospitals and as a pilot unit in the first batch of the National Twin Pregnancy Standardized Management Improvement Project, and was approved to establish a key laboratory for maternal-fetal medicine research; in 2022, it was approved as a Demonstration Unit for Characteristic Maternal and Perinatal Healthcare in Guangzhou (2022-2024); in 2023, it was approved as a National Specialty for Characteristic Pre-marital and Preconception Healthcare and as a Guangzhou Obstetrics Clinical Key Specialty (Institute of Clinical Medicine); in 2024, it was approved as a National Clinical Key Specialty of Obstetrics and successfully completed the acceptance assessment for the Guangzhou Specialty for Characteristic Maternal and Perinatal Healthcare; in 2025, it was awarded four national-level subspecialty designations in hypertensive disorders of pregnancy, preterm birth, placental diseases, and fetal medicine, as well as designation as a national-level maternal MDT construction unit for the Maternal-Fetal Medicine Outpatient Clinic, and was once again approved as a Guangzhou Specialty for Maternal and Perinatal Healthcare (2025-2027). The department has achieved fruitful results in scientific research. In 2020, it took the lead in conducting multiple multicenter clinical studies and established research collaborations with many renowned medical institutions in China and abroad, further enhancing its influence domestically and internationally. In 2021, it successfully established the Institute of Maternal-Fetal Medicine, dedicated to in-depth research and innovative treatment of maternal-fetal diseases. In 2020, the project “Basic Research and Clinical Application of Inflammatory Mechanisms in Hypertensive Disorders of Pregnancy” won the Second Prize of the Guangdong Provincial Science and Technology Progress Award; in 2022, the project “Research on the Application of High-throughput Sequencing and Gene Chip Technologies in the Prenatal Screening and Diagnosis of Chromosomal Diseases” won the Second Prize of the Guangdong Provincial Science and Technology Progress Award. In 2024, the department’s research findings were published in the international top academic journal BMJ, marking a new stage in the department’s scientific research. Over the past 5 years, it has published more than 300 SCI papers in major international academic journals, including BMJ, Nature, Lacent, NEJM, Circulation, J Physiology, and AJOG; it has received approval for 44 projects from the National Natural Science Foundation of China, 5 other national key R&D and 863 subprojects, and more than 130 provincial- and municipal-level projects. 【Specialty-Specific Technologies】 1. Fetoscopic laser coagulation of placental communicating vessels: More than 160 cases of intrauterine treatment for complex twin pregnancies (TTTS, TAPS, sIUGR, and TRAPS) have been performed in total, including more than 40 cases in 2024; 80% of the cases came from Guangzhou and outside Guangdong Province. Through continuous improvement of surgical techniques and the accumulation of experience, overall fetal survival has improved significantly, and gestational age at delivery has gradually increased. This technology was approved as a Guangzhou clinical high-tech development project, and the academic leader has repeatedly provided pioneering technical guidance outside the province and city. 2. Comprehensive technology for the prediction, prevention, and treatment of hypertensive disorders of pregnancy: 2,800 individuals at risk for hypertensive disorders of pregnancy were screened; among them, 730 were at high risk for preeclampsia, with more than 793 regular follow-up visits during pregnancy; 183 have delivered, and phased results have been achieved. 3. Comprehensive treatment of pernicious placenta: Through continuous improvement of the comprehensive surgical pathway and the use of three-dimensional reconstruction technology, a modified 3P technique for placenta accreta was developed. More than 20 uterus-preserving procedures have been successfully completed, with good outcomes. 4. Uterine electromyography monitoring technology: Uterine electromyography monitoring has been incorporated into clinical practices such as monitoring uterine power during labor and determining the timing of delivery, providing new ideas and a new basis for clinical decision-making. Uterine electromyography monitoring has also gradually evolved from a clinical high-tech technology into a routine monitoring technology, continuously broadening clinical diagnostic and treatment approaches. Further development of this project will have great significance for guiding precision obstetric medicine.